-+ 0.00%
-+ 0.00%
-+ 0.00%

NewAmsterdam Pharma Q2 net loss widens to USD 64.1 million; revenue falls to USD 3.7 million

PUBT·08/05/2026 11:11:13
Listen to the news
NewAmsterdam Pharma Q2 net loss widens to USD 64.1 million; revenue falls to USD 3.7 million
  • NewAmsterdam Pharma posted a 2Q net loss of USD 64.1 million, widening from USD 17.4 million a year earlier.
  • Revenue fell 80.66% year over year to USD 3.7 million.
  • R&D expenses climbed 51.64% to USD 41.7 million, while SG&A costs edged down 1.36% to USD 26.9 million.
  • Cash, cash equivalents and marketable securities totaled USD 678.3 million at June 30, 2026, down from USD 728.9 million at Dec. 31, 2025.
  • CHMP issued a positive opinion for obicetrapib and an obicetrapib/ezetimibe fixed-dose combination; PREVAIL interim analysis is planned for 4Q2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050700PRIMZONEFULLFEED9803684) on August 05, 2026, and is solely responsible for the information contained therein.